Our R&D strategy for a thriving product pipeline
As a global biopharmaceutical company with a focus on innovation and specialty care, Ipsen is building a strong and sustainable portfolio of medicines to meet patients’ and their healthcare teams’ needs. We prioritize best-in-class and first-in-class treatments in oncology, rare disease, and neuroscience – areas in which we have proven experience, global capabilities, and a strong network of partners.
Key facts
Investing heavily in R&D
€687m invested in R&D in 2024, sustaining a high-value pipeline.
Precision focus in 3 therapeutic areas
Since 2020, Ipsen has brought in more than 30 programs across our three focus areas of Oncology, Rare disease, and Neuroscience at every stage of development.
Investing in a strong future
Ipsen has been around for around 100 years and plan to be around for another 100. We have significant firepower to invest in the development of next-generation medicines through the pipeline.
Our expert teams and facilities
700 R&D colleagues span three global sites in France, the UK and the US, supported by dedicated research and manufacturing facilities worldwide – including state-of-the-art capabilities in Wrexham, UK to develop and produce neurotoxins.
End-to-end expertise
Ipsen execute across all stages and geographies, leveraging our global footprint, end-to-end capabilities, and scalable operations that flex to portfolio needs.
Building a high-value, sustainable pipeline
Disease Areas
Phase
Phase I
Phase II
Phase III
Registration
| Therapy Area | Compound Name | Compound Type | Indication | Trial | Phase |
|---|---|---|---|---|---|
|
|
IPN01203 |
T-Cell Activator of Vβ6 T Cells |
Solid Tumors |
NCT07213830
|
1
2
3
R
|
|
|
IPN60300 |
Antibody–Drug Conjugate Targeting ITGA2 |
Solid Tumors |
NCT07213817
|
1
2
3
R
|
|
|
IPN60340* |
BTN3A T-Cell Activator |
First Line, Unfit Acute Myeloid Leukemia |
EVICTION 3
|
1
2
3
R
|
|
|
Navtemadlin |
Mouse Double Minute 2 inhibitor |
Myelofibrosis |
POIESIS
|
1
2
3
R
|
|
|
Tovorafenib |
Type II RAF Inhibitor of the MAPK Pathway |
First-Line Pediatric Low-Grade Glioma |
FIREFLY-2*
|
1
2
3
R
|
|
|
Potravitug |
Monoclonal Antibody |
Post-Transplant Nephropathy |
SAFE KIDNEY 3
|
1
2
3
R
|
|
|
Elafibranor |
Peroxisome Proliferator-Activated Receptor α/δ agonist |
Primary Sclerosing Cholangitis |
ELASCOPE
|
1
2
3
R
|
|
|
Iqirvo |
PPAR α/δagonist |
Primary Biliary Cholangitis |
ELSPIRE
|
1
2
3
R
|
|
|
Corabotase |
Recombinant Neuroinhibitor |
Adult Upper Limb Spasticity (Therapeutics) |
LANTIMA
|
1
2
3
R
|
|
|
Corabotase |
Recombinant Neuroinhibitor |
Migraine (Therapeutics) |
MERANTI
|
1
2
3
R
|
|
|
Corabotase |
Recombinant neuroinhibitor |
Glabellar Lines (Aesthetics) |
LANTIC
|
1
2
3
R
|
|
|
Corabotase |
Recombinant Neuroinhibitor |
Cervical Dystonia (Therapeutics) |
CATALPA
|
1
2
3
R
|
|
|
Corabotase |
Recombinant Neuroinhibitor |
Glabellar Lines (Aesthetics) |
LAURITE-1
/
LAURITE-2
|
1
2
3
R
|
|
|
Dysport |
BoNTA |
Chronic Migraine |
C-BEOND
|
1
2
3
R
|
|
|
Dysport |
BoNTA |
Episodic Migraine |
E-BEOND
|
1
2
3
R
|
*Executed by Day One, a Servier Group Company **This project has been funded by the French State under France 2030 Information shown as of October 2026 – Trials are event-driven & timings can change
| RAF | Rapidly Accelerated Fibrosarcoma |
| BTN3A | Butyrophilin-3A |
| RAFi | RAF inhibitor of the MAPK pathway |
Our Partnerships
Ipsen are building a high-impact pipeline driven by external innovation. We seek to build purpose-led partnerships that boost our capacity to improve or extend the lives of people living with cancer, rare diseases and neurological conditions.
Learn moreClinical Trials
Ipsen are building a high-impact pipeline driven by external innovation. We seek to build purpose-led partnerships that boost our capacity to improve or extend the lives of people living with cancer, rare diseases and neurological conditions.